Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis … - SLUB Dresden

Media type: E-Article
Title: Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC) : final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”: (Annals of Oncology 28 (2017) (2768–2772), (S0923753419346137), (10.1093/annonc/mdx494))
Contributor: Nitz, Ulrike Anneliese [Author]; Gluz, Oleg [Author]; Christgen, Matthias [Author]; Grischke, Eva-Maria [Author]; Augustin, Doris [Author]; Kuemmel, Sherko [Author]; Braun, Michael S. [Author]; Potenberg, Jochem [Author]; Kohls, Andreas [Author]; Krauss, Katja [Author]; Reimer, Toralf [Author]
Published: March 2022
Published in: Annals of oncology ; 33(2022), 3, Seite 355
Language: English
DOI: 10.1016/j.annonc.2021.12.008
Identifier:

Search in field: